Portal de Periódicos da CAPES

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER ‐medicare analysis

2017; Wiley; Volume: 6; Issue: 12 Linguagem: Inglês

10.1002/cam4.1246

2045-7634

Sikander Ailawadhi, Ryan D. Frank, Pooja Advani, Abhisek Swaika, M’hamed Temkit, Richa Menghani, Mayank Sharma, Zahara Meghji, Shumail M. Paulus, Nandita Khera, Shahrukh K. Hashmi, Aneel Paulus, Tanya Singh Kakar, David O. Hodge, Dorin Colibaseanu, Michael Vizzini, Vivek Roy, Gerardo Colón‐Otero, Asher Chanan‐Khan,

Cancer therapeutics and mechanisms

Abstract Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial‐ethnic groups exist. Differences in utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER‐Medicare database. A utilization analysis of lenalidomide, thalidomide, bortezomib, and stem cell transplant (SCT) was performed for patients diagnosed with MM between 2007 and 2009, including use over time, use by race, time‐dependent trends for each racial subgroup, and survival analysis. A total of 5338 MM patients were included with median 2.4‐year follow‐up. Within the first year of MM diagnosis, utilization of lenalidomide, bortezomib, SCT, and more than one novel agent increased over time while utilization of thalidomide decreased. There was significantly lower utilization of lenalidomide among African‐Americans ( P < 0.01), higher thalidomide use among Hispanics and Asians ( P < 0.01), and lower bortezomib use among Asians ( P < 0.01). Hispanics had the highest median number of days to first dose of bortezomib ( P = 0.02) and the lowest utilization of SCT ( P < 0.01). Hispanics and Asians were the only groups without notable increases in lenalidomide and bortezomib use, respectively. SCT utilization increased over time for all except African‐Americans. SCT use within the first year after diagnosis was associated with better overall survival (HR 0.52; 95% CI: 0.4–0.68), while bortezomib use was associated with inferior survival (HR 1.14; 95% CI 1.02–1.28). We noted considerable variability in MM therapeutics utilization with seeming inequity for racial‐ethnic minorities. These trends should be considered to eliminate drug access and utilization disparities and achieve equitable benefit of therapeutic advances across all races.